GeneDx Holdings Corp. (NASDAQ:WGS) is currently facing scrutiny as The Rosen Law Firm investigates potential securities claims on behalf of its shareholders. This investigation was sparked by a report from Grizzly Research, which accuses GeneDx of engaging in fraudulent activities aimed at manipulating Medicaid and Medicare systems, thereby inflating its revenue figures. As a result of this report, GeneDx's stock price experienced a 6.7% drop on the day the report was published.

The Rosen Law Firm, renowned for its proficiency in securities class actions, is in the process of preparing a class action lawsuit to recover losses for investors. The firm is known for its contingency fee arrangement, which ensures that investors do not incur any out-of-pocket expenses. In 2019, The Rosen Law Firm successfully secured over $438 million for investors, including a record settlement against a Chinese company.

In the midst of these allegations, significant stock transactions by GeneDx's leadership have come to light. On June 16, 2025, CEO Katherine Stueland sold 10,501 shares at an approximate price of $64.77 each, retaining 14,597 shares. Similarly, CFO Feeley Kevin sold 3,729 shares at the same price, leaving him with 8,769 shares. These transactions have been documented in official SEC filings.

Despite the ongoing investigation, GeneDx's stock is currently trading at $67, reflecting a 3.99% increase with a $2.57 change. The stock has seen fluctuations between $63.58 and $67 today. Over the past year, the stock reached a high of $117.75 and a low of $24.91. GeneDx's market capitalization stands at approximately $1.91 billion, with a trading volume of 561,067 shares.